Guangrong Zheng
University of Florida
H-index: 33
North America-United States
Top articles of Guangrong Zheng
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer | Cells | Sajid Khan Lin Cao Janet Wiegand Peiyi Zhang Maria Zajac-Kaye | 2024/3/17 |
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL | Nature communications | Digant Nayak Dongwen Lv Yaxia Yuan Peiyi Zhang Wanyi Hu | 2024/3/29 |
Abstract 1209 Structural And Biochemical Studies Of Proteolysis-Targeting Chimera (PROTAC) Against Oncogenic Anti-Apoptotic Proteins, BCL-xl And Bcl-2 | Journal of Biological Chemistry | Digant Nayak Dongwen Lyu Wanyi Hu Guangrong Zheng Daohong Zhao | 2024/3/1 |
Attenuating breast cancer metastasis with BCL-XL-targeting PROTACs | Cancer Research | Madison E Carelock Peiyi Zhang Mo Jiao Umasankar De Zeng Jin | 2024/3/22 |
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy | Journal of Experimental Medicine | Lei Wang Yufeng Xiao Yuewan Luo Rohan P Master Jiao Mo | 2024/2/9 |
Rational targeting of BCL-xL and/or mTOR enhance the efficacy of KRASG12D inhibitor in pancreatic cancer | Cancer Research | Sajid Khan Lin Cao Vignesh Vudhata Yang Yang Peiyi Zhang | 2024/3/22 |
Design and optimization of piperlongumine analogs as potent senolytics | Bioorganic & Medicinal Chemistry Letters | Xuan Zhang Yonghan He Xingui Liu Xin Zhang Peizhong Shi | 2024/1/15 |
Discovery of hydrazide-based HDAC8 selective PROTACs | Cancer Research | Yufeng Xiao Yi Liu Nikee Awasthee Chengcheng Meng Michael He | 2024/3/22 |
YAP at the Crossroads of Biomechanics and Drug Resistance in Human Cancer | Miao Huang Heyang Wang Cole Mackey Michael C Chung Juan Guan | 2023/8/6 | |
Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader | Blood | Daisy Diaz Rohena Arnau Peris Cuesta Bailey Slawin Janani Ravikrishnan Chaomei Liu | 2023/11/28 |
Abstract LB002: Extracellular vesicle loading of proteolysis targeting chimeras for targeted therapeutic delivery | Cancer Research | Nina Erwin Xiaoshu Pan Nikee Awasthee Yufeng Xiao Guangrong Zheng | 2023/4/14 |
Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy (vol 113, pg 1285, 2021) | JNCI: Journal of the National Cancer Institute | Pataje G Prasanna Deborah E Citrin Jeffrey Hildesheim Mansoor M Ahmed Sundar Venkatachalam | 2021/10/1 |
Benzoylhydrazide-derived hdac degraders as therapeutics for treating cancer and other human diseases | 2023/6/15 | ||
HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation | Cell chemical biology | Yufeng Xiao Seth Hale Nikee Awasthee Chengcheng Meng Xuan Zhang | 2023/11/16 |
Developing a PROTAC-based NR4A1 degrader for melanoma cancer therapy | Cancer Research | Rohan Master Yuewan Luo Yufeng Xiao Daohong Zhou Lei Wang | 2023/4/4 |
Abstract B009: A liver-tropic BCL-xL PROTAC effectively clears senescent hepatocytes and prevents NASH-driven HCC in mice | Cancer Research | Yang Yang Natacha Jn-Simon Wanyi Hu Peiyi Zhang Guangrong Zheng | 2023/1/15 |
Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy | Madison E Carelock Rohan P Master Myung-Chul Kim Zeng Jin Lei Wang | 2023/6/1 | |
Therapeutic agents and methods of treatment | 2023/10/26 | ||
Selective targeting deacetylase 3 (HDAC3) and HDAC8 by PROTACs | Cancer Research | Yufeng Xiao Seth Hale Nikee Awasthee Xuan Zhang Yi Liu | 2023/4/4 |
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice | Cell Death Discovery | Sajid Khan Patrick Kellish Nick Connis Dinesh Thummuri Janet Wiegand | 2023/1/2 |
Co-Authors
